Regeneron Backs $500 Million Venture Capital Fund for Biotechnology Innovation

Regeneron Ventures announces its formation as a venture capital fund focused on promising biopharmaceutical, health care and health technology companies. The fund’s general partner will be independently managed by former Regeneron executives Jay S. Markowitz, MD, and Michael Aberman, MD, who together will lead investment strategy of the fund. Regeneron Pharmaceuticals, the maker of Eylea (aflibercept), is the fund’s exclusive limited partner and has committed $100 million annually for 5 years.[1]

“Understanding that the most groundbreaking, transformative approaches to preventing and treating disease may yet to be discovered, the fund will invest for the long-term, agnostic to therapeutic area, technology and stage of development,” said Dr. Markowitz.

Drs. Markowitz and Aberman both started their professional careers in medicine before transitioning into investing and operational roles in biotech.

“Our goal is to cultivate an ecosystem where the next generation of biotech companies can thrive, drawing on the lessons learned and successes achieved at Regeneron and throughout our careers,” said Dr. Aberman. “Together, we will strive to identify and support groundbreaking advancements that push the boundaries of what's possible in science and medicine.”

References

1. Full commitment is contingent on registration under the U.S. Investment Advisors Act of 1940.